BCRX — BIOCRYST PHARMACEUTICALS

Ownership history in WOLVERINE TRADING, LLC  ·  76 quarters on record

This page tracks every 13F SEC filing in which WOLVERINE TRADING, LLC reported a position in BIOCRYST PHARMACEUTICALS (BCRX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.01% (2016 Q4)
Avg. % of fund
0.0%
First filed
2016 Q3
Last filed
2025 Q2
Quarters held
76
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q2 REDUCED 14,300 -31,200 -68.6% 0.00% $134K $8.96
2025 Q2 ADDED 45,500 +24,200 +113.6% 0.00% $426K $8.96
2025 Q1 REDUCED 21,300 -22,000 -50.8% 0.00% $167K $7.50
2025 Q1 ADDED 43,300 +24,600 +131.6% 0.00% $340K $7.50
72 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    BCRX price (monthly, adj. close)

Other funds also holding BCRX

As of 2025 Q4 — sorted by position size

Elmind Capital, LP 4.95% Kynam Capital Management, LP 3Y 4.67% DEERFIELD MANAGEMENT COMPANY, L.P. 3Y 7Y 1.43% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 1.26% SPHERA FUNDS MANAGEMENT LTD. 3Y 7Y 1.26% Eversept Partners, LP 3Y 7Y 1.18% RICE HALL JAMES & ASSOCIATES, LLC 3Y 7Y 0.82% DAFNA Capital Management LLC 3Y 7Y 0.76% Parkman Healthcare Partners LLC 3Y 0.67% Vestal Point Capital, LP 0.6%
← Back to WOLVERINE TRADING, LLC Holdings